CURRENT REPORT 43/2020
December 1, 2020

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

The Management Board of Ryvu Therapeutics S.A. with its registered office in Cracow ("Company") hereby announces the positive results of the pharmacodynamic assay demonstrating target engagement in the dose escalation part of the DIAMOND-01 trial (CLI24-001; clinicaltrials.gov identifier NCT03008187), a study investigating SEL24/MEN1703, a first-in-class, orally available, dual PIM/FLT3 inhibitor as single agent in acute myeloid leukemia (AML), published by the Menarini Group - a global partner and sponsor of clinical trial of SEL24/MEN1703, on the basis of an exclusive license agreement concluded with the Company.

The poster entitled *"SEL24/MEN1703 provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamic (PD) Assay in the Dose Escalation Part of First-in-Human DIAMOND Trial"* will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place virtually on December 5-8.

DIAMOND-01 is the First-in-Human, Phase I/II dose escalation and cohort expansion trial of SEL24/MEN1703 for patients with relapsed or refractory AML and previously untreated patients unsuitable for chemotherapy. The study has completed the dose escalation part showing a manageable safety profile up to the recommended dose of 125 mg/day, with initial evidence of anti-leukemic activity in a single agent setting.

The positive preliminary data from the dose escalation phase of DIAMOND-01 trial shows a manageable safety profile, signs of efficacy and a meaningful target engagement in peripheral blood and bone marrow blast cells of AML patients treated with SEL24/MEN1703. Moreover, preliminary data suggest that the PIM/FLT3 pathway inhibition might be associated with blast count reduction, particularly in those patients showing high phosphorylation of S6 at baseline. Longitudinal monitoring of PD will be continued in the

cohort expansion part of the DIAMOND-01 trial, which is currently recruiting patients with relapsed or refractory AML in both the EU and the US.

Two additional posters regarding the potential therapeutic effect of PIM kinases inhibition – in both cases carried out using SEL24/MEN1703 – in other hematological cancers, namely diffuse large B-cell lymphoma and multiple myeloma, will also be published at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition:

- *"Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies"*;

- *"PIM Kinase Inhibition Decreases the Proangiogenic Properties of Multiple Myeloma Cells and Affects the Metabolic State of the Vascular Endothelium"*.

Legal basis: Article 17.1 of the Market Abuse Regulation

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board